Jose E Ales-Martinez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4433599/publications.pdf

Version: 2024-02-01

35 papers	1,635 citations	471509 17 h-index	414414 32 g-index
36 all docs	36 docs citations	36 times ranked	1823 citing authors

#	Article	IF	Citations
1	SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). Clinical and Translational Oncology, 2020, 22, 193-200.	2.4	52
2	Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Breast, 2020, 54, 286-292.	2.2	4
3	182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy. Annals of Oncology, 2020, 31, S82.	1.2	0
4	Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. Psycho-Oncology, 2018, 27, 1530-1537.	2.3	30
5	SEOMâ€“SERAMâ€“SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. Clinical and Translational Oncology, 2018, 20, 837-852.	2.4	9
6	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Targeted Oncology, 2018, 13, 69-78.	3.6	0
7	Relationship of axillary total tumoral load (TTL) in early breast cancer and local and distant clinical outcomes.. Journal of Clinical Oncology, 2018, 36, e12574-e12574.	1.6	0
8	Impact of the Prosigna (PAM50) assay on adjuvant clinical decision making in patients with early stage breast cancer: Results of a prospective multicenter public program.. Journal of Clinical Oncology, 2017, 35, e12062-e12062.	1.6	1
9	Preventive treatments for breast cancer: recent developments. Clinical and Translational Oncology, 2015, 17, 257-263.	2.4	8
10	Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1427-1436.	1.6	49
11	Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients.. Journal of Clinical Oncology, 2014, 32, e11513-e11513.	1.6	3
12	Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Research and Treatment, 2013, 138, 249-259.	2.5	23
13	Exemestane versus anastrozole as frontâ€line endocrine therapy in postmenopausal patients with hormone receptorâ€positive, advanced breast cancer. Cancer, 2012, 118, 241-247.	4.1	25
14	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011, 364, 2381-2391.	27.0	847
15	National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of Exemestane to Prevent Breast Cancer in Postmenopausal Women. Clinical Breast Cancer, 2007, 7, 895-900.	2.4	19
16	Low dose Gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clinical and Translational Oncology, 2007, 9, 459-464.	2.4	9
17	Tailored low-dose gemcitabine-cisplatin combination is a feasible and effective treatment in heavily pretreated advanced breast cancer patients. Journal of Clinical Oncology, 2005, 23, 837-837.	1.6	2
18	Do changes in dietary salt influence blood pressure of hypertensive patients pharmacologically controlled with verapamil? The Salt-Switching-Study (SSS). Journal of Human Hypertension, 1995, 9, 143-7.	2.2	3

#	Article	IF	Citations
19	Signal Transduction Pathways Involved in B-Cell Induction. Immunological Reviews, 1993, 132, 5-48.	6.0	45
20	Programmed cell death by bcl-2-dependent and independent mechanisms in B lymphoma cells. EMBO Journal, 1993, 12, 1555-60.	7.8	35
21	Interleukin-2: A Possible Trigger for Autoimmunity. International Archives of Allergy and Immunology, 1992, 97, 251-257.	2.1	17
22	Prostaglandin E2 induces apoptosis in immature normal and malignant B lymphocytes. Clinical Immunology and Immunopathology, 1992, 63, 221-229.	2.0	77
23	The parameters of B-cell inactivation in transgenic mice vs classical model studies. Research in Immunology, 1992, 143, 279-285.	0.9	2
24	Inability of IL-2 and IL-10 to counteract B cell clonal deletion. Cellular Immunology, 1992, 142, 94-102.	3.0	3
25	Cross-linking of surface IgM or IgD causes differential biological effects in spite of overlap in tyrosine (de)phosphorylation profile. European Journal of Immunology, 1992, 22, 845-850.	2.9	26
26	Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway. European Journal of Immunology, 1992, 22, 1007-1011.	2.9	67
27	Prevention of B cell clonal deletion and anergy by activated T cells and their lymphokines. Seminars in Immunology, 1992, 4, 195-202.	5.6	6
28	Signalling in B cells. Trends in Immunology, 1991, 12, 201-205.	7.5	51
29	Lymphoma models for B-cell activation and tolerance. Cellular Immunology, 1991, 135, 402-409.	3.0	14
30	Lymphoma models for B cell activation and tolerance. Cellular Immunology, 1990, 127, 527-534.	3.0	14
31	Regulation of natural killer cytotoxicity by 1,25-dihydroxyvitamin D3. Cellular Immunology, 1989, 118, 328-336.	3.0	48
32	Models of B-cell Unresponsiveness. Cold Spring Harbor Symposia on Quantitative Biology, 1989, 54, 899-905.	1.1	6
33	Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer, 1988, 61, 629-634.	4.1	26
34	Decreased TcR-CD3+ T cell numbers in healthy aged humans. Evidence that T cell defects are masked by a reciprocal increase of TcR-CD3â^'CD2+ natural killer cells. European Journal of Immunology, 1988, 18, 1827-1830.	2.9	39
35	Immunoglobulins D and M mediate signals that are qualitatively different in B cells with an immature phenotype.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 6919-6923.	7.1	75